EP3091029
And-IL13 mótefnasamsetningar
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
30.10.2012EP published:
28.12.2022EP application number:
16169916.0
EP translation filed:
6.2.2023Grant published:
15.3.2023EPO information:
European Patent Register
Max expiry date:
29.10.2032Expiry date:
29.10.2026Next due date:
31.10.2026
Title in English:
ANTI-IL13 ANTIBODY FORMULATIONSLanguage of the patent:
English
Timeline
Today
30.10.2012EP application
28.12.2022EP Publication
6.2.2023Translation submitted
15.3.2023Registration published
29.10.2026Expires
Owner
Name:
F. Hoffmann-La Roche AGAddress:
Grenzacherstrasse 124, 4070 Basel, CH
Inventor
Name:
DESHMUKH, AjayAddress:
South San Francisco, CA 94080, US
Name:
ZEID, JoumanaAddress:
South San Francisco, CA 94080, US
Name:
SCHERER, Thomas M.Address:
South San Francisco, CA 94080, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201161553916 PDate:
31.10.2011Country:
US
Classification
Categories:
A61P 37/08
Annual fees
Number
Paid
Expires
Payer
Number: 12
Paid: 6.10.2023
Expires: 29.10.2024
Payer: Árnason Faktor ehf.
Number: 13
Paid: 23.9.2024
Expires: 29.10.2025
Payer: Árnason Faktor ehf.
Number: 14
Paid: 16.10.2025
Expires: 29.10.2026
Payer: Árnason Faktor ehf.